Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)

Hubei Goto Biopharm Group Revenue

In the year 2025, Hubei Goto Biopharm Group had annual revenue of 606.18M CNY with 12.97% growth. Hubei Goto Biopharm Group had revenue of 161.94M in the quarter ending March 31, 2026, with 16.32% growth.

• Revenue: 606.18M
• Revenue Growth: +12.97%
• P/S Ratio: 5.14
• Revenue / Employee: 741.96K
• Employees: 817
• Market Cap: 3.12B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	606.18M	69.58M	12.97%
Dec 31, 2024	536.60M	-29.80M	-5.26%
Dec 31, 2023	566.40M	-38.17M	-6.31%
Jan 1, 2023	604.57M	13.69M	2.32%
Jan 1, 2022	590.89M	122.77M	26.23%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 20, 2026

Data Sources Report a data error